Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

mscs

  • Home
  •  
  • mscs



  • Most Read
  • Latest Comments
  • Cynata teams up with Leiden University Medical Center to test its stem cell solution on kidney transplant patients
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Cynata teams up with Leiden University Medical Center to test its stem cell solution on kidney transplant patients
    • Satire

    Australia to close borders to Omicron Persei 8
    Public
  • Cynata teams up with Leiden University Medical Center to test its stem cell solution on kidney transplant patients
    • Opinion

    The New Criterion: will the listed sanitiser stocks clean up – or clean out – investors?
    Public
  • Cynata teams up with Leiden University Medical Center to test its stem cell solution on kidney transplant patients
    • Opinion

    Is this the most hated company on the ASX?
    Public
  • Cynata teams up with Leiden University Medical Center to test its stem cell solution on kidney transplant patients
    Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Imagion Biosystems Advances MagSense® Phase 2 Trial
    Imagion Biosystems Advances MagSense® Phase 2 Trial
    • News

  • Acrux-developed Menopause Hormone Therapy to enter Australian market
    Acrux-developed Menopause Hormone Therapy to enter Australian market
    • News

  • Actinogen’s Phase 2a clinical trial for depression treatment fails to meet primary endpoint, shares tank
    Actinogen’s Phase 2a clinical trial for depression treatment fails to meet primary endpoint, shares tank
    • News

  • Holista Colltech banks on new partners to turn fortunes as food sales struggle
    Holista Colltech banks on new partners to turn fortunes as food sales struggle
    • News

  • Zelira Therapeutics nears clinical trial stage for Autism drug following positive FDA feedback
    Zelira Therapeutics nears clinical trial stage for Autism drug following positive FDA feedback
    • News

  • Cynata teams up with Leiden University Medical Center to test its stem cell solution on kidney transplant patients
    • News

    Cynata teams up with Leiden University Medical Center to test its stem cell solution on kidney transplant patients

    For the past few years, stem cells have come out on top as a reliable solution to many health concerns, from diabetes to cancer. Clinical stage BioTech company Cynata Therapeutics (ASX: CYP) has been testing stem cell therapy for kidney transplant patients. The Company announced that Leiden University Medical Center (LUMC) is funding an important

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.